Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00308633 · ClinicalTrials.gov registry record
Endothelial Progenitor Cells and Nitric Oxide in Cardiac Rehabilitation Program Participants
A clinical trial of Coronary Artery Disease (CAD), sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- 55
- Enrollment target
- 2
- Study locations
NCT00308633: Completed study of Coronary Artery Disease (CAD), sponsored by National Heart, Lung, and Blood Institute (NHLBI).
NCT00308633 is a study of Coronary Artery Disease (CAD) that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 55 participants, below the 1,133-participant average among 5 other Coronary Artery Disease (CAD) trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00308633, a study of Coronary Artery Disease (CAD), has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- 55 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will measure blood levels of endothelial progenitor cells (EPCs) and nitric oxide (NO) in patients with coronary artery disease (CAD) who are participating in a 3-month cardiac rehabilitation program at Suburban Hospital in Bethesda, MD. EPCs are a kind of stem cell produced by the bone marrow that can develop into cells found in arteries and in the heart and, therefore, can repair diseased vessels. The study will examine whether the EPCs are affected by exercise and will look at how they may contribute to repair of cells lining the diseased arteries as a result of participation in the rehabilitation program. People with coronary artery disease may be eligible for this study. Candidates are screened with a medical history, physical examination, electrocardiogram, and blood tests. CAD patients also to a treadmill exercise test. Volunteers' participation ends at the screening visit. The blood drawn at screening is used to identify EPC specific genes to compare with the EPC genes from patients with CAD. CAD patients participate in Suburban Hospital's cardiac rehabilitation program. The exercise portion of the program includes 36 sessions of about 60 minutes each, spaced over approximately 3 months. Patients have a baseline blood test at screening and repeat blood tests at the end of each month of participation in the rehabilitation program. Some of the blood will be used for genetic tests to see how genes of the EPCs are changed by the patient's participation in the rehabilitation program.
Conditions Studied
Study Locations (2)
Maryland
- Suburban Hospital - Bethesda
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2006-03-23 |
What the finished NCT00308633 record still lists
NCT00308633 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 1,133-participant average among 5 other Coronary Artery Disease (CAD) trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Coronary Artery Disease (CAD) appearing as the primary indexed condition, and to 0 interventions.
NCT00308633 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00308633 about?
NCT00308633 is a clinical study titled "Endothelial Progenitor Cells and Nitric Oxide in Cardiac Rehabilitation Program Participants". This study will measure blood levels of endothelial progenitor cells (EPCs) and nitric oxide (NO) in patients with coronary artery disease (CAD) who are participating in a 3-month cardiac rehabilitation program at Suburban Hospital in Bethesda, MD. EPCs are a kind of stem cell produced by the bone m...
What is the current status of trial NCT00308633?
This trial is currently completed. The enrollment target is 55 participants. The study started on 2006-03-23.
What conditions does trial NCT00308633 study?
This clinical trial studies the following conditions: Coronary Artery Disease (CAD).
Who is sponsoring clinical trial NCT00308633?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00308633 being conducted?
This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease (CAD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The NAVIGATE-PCI Registry: A New Approach to VIew CT-derived Guidance Ahead of Stenting To Plan Efficient PCI
RECRUITING
-
Using CTA Measures to Define Cardiac Risk In NFL Alumni
RECRUITING
-
Beating the Blues for Your Heart
COMPLETED · Phase 2
-
A Study to Assess the Engagement and Usefulness of Care4Today Digital Platform for Disease Management in Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD) Population
COMPLETED
-
Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI